

## IN THE CLAIMS:

- 1. (currently amended) A method for detecting prostate cancer, comprising:
  - a) providing a serum sample from a subject suspected of having cancer; and
- b) detecting the presence or absence of antibodies to Huntingtin Interacting
  Protein 1 (HIP1) in said serum sample, wherein the presence of antibodies to HIP1 in said
  sample is indicative of prostate cancer in said subject, and the absence of antibodies to
  HIP1 in said sample is indicative of the absence of prostate cancer in said subject.
- 2-3. (canceled)
- 4. (original) The method of Claim 1, wherein said sample is a tumor sample.
- 5. (original) The method of Claim 1, wherein said sample is a tissue sample.
- 6. (previously presented) The method of Claim 5, wherein said tissue sample is prostate tissue.
- 7. (original) The method of Claim 1, wherein said sample is selected from the group consisting of serum, plasma, blood, and urine.
- 8. (original) The method of claim 1, wherein said detecting comprises exposing said sample to a HIP1 antigen.
  - 9. (original) The method of claim 8, wherein said detecting comprises a Western blot.
  - 10. (original) The method of claim 8, wherein said detecting comprises an ELISA assay.
- 11. (original) The method of claim 1, wherein said detecting comprises exposing said sample to a second antibody that binds to said antibody to HIP1.